Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.


Advances in Alzheimer’s Disease Therapeutics

Advances in Alzheimer’s Disease Therapeutics
Reported by
Rebecca Vaadia

Posted February 20, 2020

Rebecca Vaadia is a PhD candidate in neuroscience and a science communicator in New York.

Presented By

Brain and Behavior Discussion Group

The New York Academy of Sciences


For decades, Alzheimer's disease (AD) research has focused on amyloid beta (Ab) aggregation as the main driver of disease and a promising target for treatment. However, the recent failure of multiple Phase III clinical trials focused on Ab have highlighted the need for different approaches. Many researchers are now working to uncover alternative mechanisms that contribute to disease, and potential treatments that can target these pathways. Reflecting the complexity of the disease, promising pathways are diverse and include neuroinflammation, tau propagation, and metabolic processes. Since AD is a heterogeneous and progressive disease, researchers are also working to develop biomarkers that can identify patients at the appropriate disease stage for a specific therapeutic. Learn more about recent breakthroughs in understanding Alzheimer's disease in this summary of our November 20th, 2019 symposium, which gathered the world’s leaders in the field.

Symposium Highlights

  • Differential rates of clinical AD progression in humans are associated with differences in tau properties, implicating tau as a promising target. >
  • The TREM2 receptor is required for microglial activation in mice and humans, which may be therapeutic in early disease stages. >
  • Hyperexcitability is a promising therapeutic target: low-dose levetiracetam reduces hippocampal hyperactivity and improves memory task performance in patients with Mild Cognitive Impairment. >
  • Circulating High Density Lipoprotein (HDL) improves Ab clearance in a bioengineered human tissue culture model. >
  • The gut microbiome influences neuroinflammation and amyloid deposition, but only in male animals. >
Perspectives on the Future of Alzheimer’s Disease Research
Neuroinflammation as a Driver of Disease
Risk Factors, Biomarkers and Early Detection
Emerging Mechanistic Insights for Alzheimer’s Disease